SARS-Cov-2 Neutralizing Antibody Test

Identify individuals who lack neutralizing antibodies so they can be informed and kept safe!

Pharmacogenetic (PGx)

Clinical Utility

CoreBioLabs’ Covid-19 Neutralizing Antibody Test is for qualitative testing of human blood and serum for the presence of neutralizing antibodies to SARS-CoV-2 virus. Neutralizing antibodies are like the special forces of the immune response disarming the virus at just the right point before it can attack our cells. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Many different antibodies are elicited from SARS-CoV-2 infection or vaccination but only a subset handcuff the virus so it can’t take control of the cells and spread.

Recent studies have identified a decline in neutralization titer with time for up to 8 months after SARS-CoV-2 infection. However, the duration of protective immunity is presently unclear, primary immune responses varies of increasingly concerning viral variants. Vaccine efficacies from 50 to 95% have been reported; a major question is whether vaccine-induced responses may be more durable than those measured following infection.

Our Assay

We detect the key immune response antibodies that shield the cells from the virus preventing infection propagation. It basically measures antibodies that actually stop the virus from binding to cells and propagating infection.

Target Applications

  • Detection of SARS-CoV-2 neutralizing (virus blocking) antibodies in the serum from recovering COVID-19 patients.
  • Detection of SARS-CoV-2 neutralizing (virus blocking) antibodies in the serum from vaccinated patients.

Resources